· Original article
SITE Centers shares jump 18.3% as NYSE delisting plan emerges
SITE Centers shares rose 18.3% before trading on October 16, 2026, as a company filing outlined plans to voluntarily leave the NYSE in December.
FINANCEVELIX / News
Listed companies, earnings, corporate developments and equity markets. Company and asset tags identify the subjects of a story.
Read the original source and publication date in each article.
Results: 1,876 · Page 65 / 157
· Original article
SITE Centers shares rose 18.3% before trading on October 16, 2026, as a company filing outlined plans to voluntarily leave the NYSE in December.
· Original article
Dynex earnings are due October 19, 2026, before market open. Analysts expect lower quarterly EPS, with management’s call scheduled for 10 a.m. ET.
· Original article
Cleveland-Cliffs earnings are due October 19, 2026. Analysts expect positive EPS and higher revenue as investors assess profitability and cash flow.
· Original article
The USAC distribution remains $0.525 per unit, payable November 6, 2026. Earlier debt pricing specified repayment of credit-agreement borrowings.
· Original article
Travelers results showed higher third-quarter profit, record investment income and $1.5 billion in buybacks, while catastrophe losses increased.
· Original article
AI shopping highlights contrasting retailer strategies, with Walmart planning ChatGPT checkout and Amazon resisting Perplexity’s shopping agent.
· Original article
Lemon Tree Hotels' subsidiary signs an MoU with Omaxe for about 4,000 rooms in India, taking its development pipeline to nearly 16,000 rooms.
· Original article
NuRAN expansion plans target 1,650 operating sites by mid-2028, subject to financing, as its CEO prepares for November telecom meetings in Cape Town.
· Original article
US stocks diverged on October 16, 2026, as chipmakers and AI infrastructure shares fell while bank gains helped support the Dow.
· Original article
Propanc PRP research shows preclinical effects in chemotherapy-resistant pancreatic cancer cells, with a first-in-human study planned for Q1 2027.
· Original article
Actinium announced preclinical ATNM-400 data across lung, colorectal and ovarian cancer models ahead of EANM 2026 presentations in Vienna.
· Original article
The Foundayo recommendation disclosed on October 16 advances Eli Lilly’s adult type 2 diabetes application, but is not a final marketing authorization.
Charts and market data by TradingView. Availability and delays vary by exchange.